Outlook Therapeutics (OTLK) Cost of Revenue (2025 - 2026)

Outlook Therapeutics (OTLK) posted quarterly Cost of Revenue of $149327.0 for Q1 2026, up 404.04% quarter-over-quarter from $29626.0 in Q4 2025.

Outlook Therapeutics (OTLK) Cost of Revenue (2025 - 2026) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Cost of Revenue for 2 consecutive years, with $149327.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Cost of Revenue changed N/A year-over-year to $149327.0; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, changed N/A from the prior year.
Cost of Revenue climbed to $149327.0 in Q1 2026 per OTLK's latest filing, from $29626.0 in the prior quarter.
Across five years, Cost of Revenue topped out at $916515.0 in Q3 2025 and bottomed at $29626.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	93.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	174.53 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	298.26 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	387.98 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	67.21 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Outlook Therapeutics	88.50 Mn	77.26 Mn	-8,265.00	16,965.00

Download Data